Mielolipoma suprarrenal atípico en paciente con hipertensión arterial resistente

  1. Toledano, María 1
  2. Encalada-Luna, Karen 1
  3. Moreno, Solsireé 2
  4. Ramón-Botella, Enrique 3
  5. Torres-Do Rego, Ana 1
  6. Bello-Martínez, Elena 1
  1. 1 Servicio de Medicina Interna, Hospital General Universitario Gregorio Marañón, Madrid, España
  2. 2 Servicio de Anatomía Patológica, Hospital General Universitario Gregorio Marañón, Madrid, España
  3. 3 Servicio de Radiodiagnóstico, Hospital General Universitario Gregorio Marañón, Madrid, España
Montrer des affiliations +
Revue:
Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

ISSN: 2530-0792

Année de publication: 2022

Titre de la publication: Spanish Journal of Case Records in Internal Medicine

Volumen: 7

Número: 2

Pages: 12-14

Type: Article

DOI: 10.32818/RECCMI.A7N2A5 DIALNET GOOGLE SCHOLAR lock_openAccès ouvert editor

D'autres publications dans: Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

Résumé

Adrenal myelolipoma is a slow-growing tumour, composed of fatty tissue and haematopoietic elements, typically non-secretory, although a low percentage is associated with endocrine pathology. We present the case of a 35-year-old man who, during the study of resistant arterial hypertension, was diagnosed with a large adrenal incidentaloma with an image congruent with adrenal myelolipoma, whose analytical determinations were anodyne, suggesting a non-functioning adenoma. After surgical resection, the anatomopathological study of the mass revealed pheochromocytoma cells, which produce catecholamines and are responsible for the patient's high blood pressure resistance.

Références bibliographiques

  • Oliveira Caiafa R, Salvador Izquierdo R, Buñesch Villalba L, Sebastià Cerqueda MC, Nicolau Molina C. Manejo y diagnóstico del incidentaloma suprarrenal. Radiologia. 2011;53(6): 516-30. doi: https://doi.org/10.1016/j.rx.2011.06.006.
  • Pérez Martínez J, Llamas F, López Rubio E, Serrano A, Salinas Sánchez A, Ruiz Mondéjar R et al. Mielolipoma suprarrenal gigante: hipertensión, insuficiencia renal y rotura espontánea. Nefrologia. 2006; 26(1): 132-5.
  • Decmann Á, Perge P, Tóth M, Igaz P. Adrenal myelolipoma: a comprehensive review. Endocrine. 2018; 59(1): 7-15. doi: https://doi.org/10.1007/s12020-017-1473-4.
  • Guerrero MA, Schreinemakers JM, Vriens MR, Suh I, Hwang J, Shen WT et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009; 209(6): 727-32. doi: https://doi.org/10.1016/j.jamcollsurg.2009.09.022.
  • Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc. 1981; 56(6): 354-60.
  • Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983; 58(12): 802-4.
  • Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004; 150(5): 681-6. doi: https://doi.org/10.1530/eje.0.1500681.
  • Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003; 88(2): 553-8. doi: https://doi.org/10.1210/jc.2002-021251.
  • Aliasgari M, Ghadian A. Coincidence of angiomyolipoma and pheochromocytoma. Urol J. 2006; 3(1): 61-4. doi: https://doi.org/10.22037/uj.v3i1.217.
La source de données: Dialnet